Real life experience on the effect of Belimumab in patients with active systemic lupus
نویسندگان
چکیده
INTRODUCTION To evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus. CASE PRESENTATION Twenty patinets with musclesketal symptoms were evaluated, three were discontinued for different resons and seventeen completed eight injections of Belimumab during a six month period. A fatigue score was also evaluated at the same time. DISCUSSION AND EVALUATION Marked reduction of disease activity and fatigue score were observed in the patient group. CONCLUSIONS Belimumab is a novel form of therapy in patients with active systemic lupus erythematosus to be added in the standard of care particularly in patients with skin and joint symptoms.
منابع مشابه
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
OBJECTIVE To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score >/=4 (n = 449)...
متن کاملEffects of belimumab in Colombian patients with systemic lupus erythematosus; a prospective observational study
Introduction: Belimumab, a monoclonal type Ig G1 antibody that binds and inhibits the soluble form of the Blys (B lymphocyte stimulator) has shown to be effective in the management of systemic lupus erythematosus (SLE). However, its effectiveness is unknown in an ethnically variable population, such as in Colombia. Methods: A prospective observational study was conducted between February 2015 a...
متن کاملA randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus
Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United Sta...
متن کاملAn update on belimumab for the treatment of lupus
B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence of efficacy in several preclinical and clinical studies in SLE. Two recent large randomized controlled trials yielded a signif...
متن کاملHealth Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
OBJECTIVE Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics. Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease. This paper summarizes a health technology assessment performed in Italy. METHODS SLE epidemiology and burden were assessed using the best published international and ...
متن کامل